BRAF and metastatic melanoma: Nivolumab is approved in the United States for the treatment of unresectable or metastatic melanoma as a single agent in patients with disease progression following ipilimumab (Yervoy) and, if positive for BRAF V600 mutation, a BRAF inhibitor.